Compare CDNA & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDNA | DRTS |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 121 |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 978.2M |
| IPO Year | 2007 | N/A |
| Metric | CDNA | DRTS |
|---|---|---|
| Price | $24.08 | $9.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $28.00 | $8.67 |
| AVG Volume (30 Days) | 652.3K | ★ 1.0M |
| Earning Date | 04-28-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $48,324,000.00 | N/A |
| Revenue This Year | $16.01 | N/A |
| Revenue Next Year | $11.31 | $699.98 |
| P/E Ratio | $469.20 | ★ N/A |
| Revenue Growth | ★ 18.93 | N/A |
| 52 Week Low | $10.96 | $2.87 |
| 52 Week High | $24.02 | $11.62 |
| Indicator | CDNA | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 65.75 | 52.11 |
| Support Level | $15.80 | $6.59 |
| Resistance Level | N/A | $11.48 |
| Average True Range (ATR) | 1.04 | 0.95 |
| MACD | 0.09 | -0.18 |
| Stochastic Oscillator | 93.00 | 39.15 |
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.